ESTRO 2024 - Abstract Book

S2403

Clinical - Urology

ESTRO 2024

relapse, a boost (sequential or concomitant) was delivered on the macroscopic recurrence. Comparing the cohorts of patients with or without mpMRI, the first group recorded a significantly higher rate of biochemical relapse-free survival rate (4-year: 74.8% versus 60.7%; p=.039; Figure 1).

Figure 1: Biochemical relapse-free survival in patients undergoing MRI (red) and not undergoing MRI (blue) before salvage radiotherapy (p=.039).

Conclusion:

An unexpected and surprisingly high rate of macroscopic relapses was recorded in patients undergoing mpMRI before sRT. This allowed treatment modulation by delivering a boost to the site of recurrence. This strategy produced a significant improvement of the biochemical outcome. Our findings challenge current guidelines on pre sRT restaging.

Keywords: mpMRI, salvage radiotherapy, prostate cancer

1151

Digital Poster

Role of 68Ga-PSMA PET/CT before early salvage radiotherapy in prostate carcinoma.

Elena Natoli 1,2 , Letizia Cavallini 1,2 , Alessandra Arcelli 1 , Filippo Mammini 1,2 , Silvia Paolinelli 1,2 , Erika Galietta 1,2 , Viola Laghi 1,2 , Milly Buwenge 2 , Giorgio Coco 1,2 , Alessandra D'Alterio 1,2 , Angelo Morattan 2,3 , Sara Tamburini 2,3 , Matteo Droghetti 2,3 , Francesco Chessa 2,3 , Calogero Catanzaro 2,3 , Lorenzo Bianchi 2,3 , Riccardo Schiavina 2,3 , Eugenio Brunocilla 2,3 , Paolo Castellucci 2,3 , Stefano Fanti 2,4 , Silvia Cammelli 1,2 , Maria Ntreta 1,2 , Alessio Giuseppe Morganti 1,2 1 Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 2 Department of Medical and Surgical Sciences (DIMEC), ), Alma Mater Studiorum University, Bologna, Italy. 3 Department of Urology, IRCCS